Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an…
| Price | $151.67 |
|---|---|
| Market cap | $188.31B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NASDAQ |
| 52-week range | 108.46-157.29 |
| Dividend (TTM) | $3.25 per share |
| Beta | 0.35 |
Explore GILD's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.